Crossmark

A network pharmacology approach confirms Biejiaxiaozheng pills combat hepatic fibrosis by modulating macrophage inflammation and hepatic stellate cell activation

Crossref DOI link: https://doi.org/10.1038/s41598-025-09002-1

Published Online: 2025-07-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Weibin

Liao, Yanli

Liang, Jiefei

Huang, Mi

Zhang, Guifeng

Hu, Yuying

Yuan, Chao

Li, Duanzhou
Funding

Funding for this research was provided by:

Zhaoqing Medical College Fund for Young Talent (Zqyq22-010, Zqyq22-010, Zqyq22-010)

Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515220194, 2022A1515220194, 2022A1515220194, 2022A1515220194, 2022A1515220194)
License Information

Text and Data Mining valid from 2025-07-09

Version of Record valid from 2025-07-09
More Information

Article History

Received: 22 November 2024

Accepted: 24 June 2025

First Online: 9 July 2025

Declarations

:

: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Document is current

Any future updates will be listed below